These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 35961968)
1. Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance. Deng Y; Diepstraten ST; Potts MA; Giner G; Trezise S; Ng AP; Healey G; Kane SR; Cooray A; Behrens K; Heidersbach A; Kueh AJ; Pal M; Wilcox S; Tai L; Alexander WS; Visvader JE; Nutt SL; Strasser A; Haley B; Zhao Q; Kelly GL; Herold MJ Nat Commun; 2022 Aug; 13(1):4739. PubMed ID: 35961968 [TBL] [Abstract][Full Text] [Related]
2. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886 [TBL] [Abstract][Full Text] [Related]
3. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053 [TBL] [Abstract][Full Text] [Related]
4. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304 [No Abstract] [Full Text] [Related]
5. Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells. Mensink M; Anstee NS; Robati M; Schenk RL; Herold MJ; Cory S; Vandenberg CJ Cell Death Differ; 2018 Mar; 25(4):797-808. PubMed ID: 29339775 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of Ravà M; D'Andrea A; Nicoli P; Gritti I; Donati G; Doni M; Giorgio M; Olivero D; Amati B Sci Transl Med; 2018 Jan; 10(426):. PubMed ID: 29386360 [TBL] [Abstract][Full Text] [Related]
7. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. Lee YG; Guruprasad P; Ghilardi G; Pajarillo R; Sauter CT; Patel R; Ballard HJ; Hong SJ; Chun I; Yang N; Amelsberg KV; Cummins KD; Svoboda J; Gill S; Chong EA; North K; Church SE; Fraietta JA; Chang WJ; Lacey SF; Lu XM; Zhang Y; Whig K; Schultz DC; Cherry S; Gerson J; Schuster SJ; Porazzi P; Ruella M Cancer Discov; 2022 Oct; 12(10):2372-2391. PubMed ID: 35904479 [TBL] [Abstract][Full Text] [Related]
8. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655 [TBL] [Abstract][Full Text] [Related]
9. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Mason KD; Vandenberg CJ; Scott CL; Wei AH; Cory S; Huang DC; Roberts AW Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17961-6. PubMed ID: 19004807 [TBL] [Abstract][Full Text] [Related]
10. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Vandenberg CJ; Cory S Blood; 2013 Mar; 121(12):2285-8. PubMed ID: 23341542 [TBL] [Abstract][Full Text] [Related]
11. BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. Cummin TEC; Cox KL; Murray TD; Turaj AH; Dunning L; English VL; Fell R; Packham G; Ma Y; Powell B; Johnson PWM; Cragg MS; Carter MJ Blood Adv; 2020 Jul; 4(14):3316-3328. PubMed ID: 32717030 [TBL] [Abstract][Full Text] [Related]
12. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321 [TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. Luo C; Yu T; Young KH; Yu L J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760 [TBL] [Abstract][Full Text] [Related]